6
Jul 2026
New viral insights lay foundation for treating infection with JC polyomaviruses
In people with severely compromised immune systems, the JC polyomavirus can trigger a currently untreatable, usually fatal brain disease.
STAY INFORMED!
6
Jul 2026
New HIV vaccine successfully generates broadly neutralizing antibodies in primates
A new HIV vaccine developed by La Jolla Institute for Immunology (LJI), Scripps Research scientists, and IAVI has the potential to protect humans from developing HIV infection and AIDS.
6
Jul 2026
Study identifies promising drug target to prevent neurodegenerative conditions
Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than ten million people worldwide. While current therapies address disease symptoms, they do not prevent the underlying neurodegeneration that drives the disease.
6
Jul 2026
New spatially resolved transcriptomic map reveals how bone and muscle cells communicate
A new study generated one of the most comprehensive spatially resolved transcriptomic maps of cellular communication between bone and skeletal muscle in a young mouse.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.